Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from TDF-containing antiretroviral regimens to E/C/F/TAF in virologically suppressed adults with HIV-1
NL-OMON40276Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of subjects with HIV-1 RNA <50 copies/mL at Week 48. Started Oct 2013; status: active, not recruiting.
02
Drugs
elvitegravircobicistatemtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON40276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40276.